Dedra Lyden - TherapeuticsMD Vice Initiatives
| TXMD Stock | USD 0.87 0.01 1.16% |
Executive
Dedra Lyden is Vice Initiatives of TherapeuticsMD
| Address | 951 Yamato Road, Boca Raton, FL, United States, 33431 |
| Phone | 561 961 1900 |
| Web | https://www.therapeuticsmd.com |
TherapeuticsMD Management Efficiency
The company has return on total asset (ROA) of (0.0665) % which means that it has lost $0.0665 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1439) %, meaning that it created substantial loss on money invested by shareholders. TherapeuticsMD's management efficiency ratios could be used to measure how well TherapeuticsMD manages its routine affairs as well as how well it operates its assets and liabilities. As of March 7, 2025, Return On Tangible Assets is expected to decline to -0.33. In addition to that, Return On Capital Employed is expected to decline to -0.28. At present, TherapeuticsMD's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 22.4 M, whereas Other Assets are forecasted to decline to 1.09.TherapeuticsMD currently holds 8.01 M in liabilities with Debt to Equity (D/E) ratio of 0.67, which is about average as compared to similar companies. TherapeuticsMD has a current ratio of 0.56, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about TherapeuticsMD's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sandra Coombs | Alkermes Plc | N/A | |
| MBA MD | Aquestive Therapeutics | 68 | |
| John Shulman | Petros Pharmaceuticals | 61 | |
| Marcel Moulaison | Ironwood Pharmaceuticals | N/A | |
| Iain Brown | Alkermes Plc | 56 | |
| Michael Lisjak | Cyclo Therapeutics | 51 | |
| Robert Arnold | Aquestive Therapeutics | N/A | |
| Jennifer Henry | Alpha Teknova | N/A | |
| Stephen DMD | Painreform | N/A | |
| Andrew Davis | Ironwood Pharmaceuticals | 38 | |
| Mary MD | ANI Pharmaceuticals | N/A | |
| Mike Nanfito | Ironwood Pharmaceuticals | N/A | |
| Thomas Guldager | Lifecore Biomedical | N/A | |
| Michael MD | Ironwood Pharmaceuticals | 66 | |
| Karen FFPM | Cyclo Therapeutics | N/A | |
| Rita Keynan | Painreform | 56 | |
| Stephen Schiavo | Alkermes Plc | N/A | |
| Thomas Rowland | ANI Pharmaceuticals | 57 | |
| Adam Mostafa | Cumberland Pharmaceuticals | 44 | |
| Declan OConnor | Alkermes Plc | N/A | |
| Blair Jackson | Alkermes Plc | 52 | |
Management Performance
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0665 |
TherapeuticsMD Leadership Team
Elected by the shareholders, the TherapeuticsMD's board of directors comprises two types of representatives: TherapeuticsMD inside directors who are chosen from within the company, and outside directors, selected externally and held independent of TherapeuticsMD. The board's role is to monitor TherapeuticsMD's management team and ensure that shareholders' interests are well served. TherapeuticsMD's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, TherapeuticsMD's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hugh MBA, Pres Director | ||
| MD FACOG, CoFounder,CoCEO Officer | ||
| Douglas Steelman, Vice Access | ||
| Benjamin Foulk, Vice Resources | ||
| Dedra Lyden, Vice Initiatives | ||
| Joseph Ziegler, Principal Officer | ||
| Daniella Silva, Chief Officer | ||
| Mark Glickman, CoCEO Officer | ||
| Robert Finizio, Co-Founder, CEO and Director | ||
| Mitchell Krassan, Executive VP and Chief Strategy Performance Officer | ||
| Michael Donegan, Vice President - Finance | ||
| Governor Thompson, Executive Chairman | ||
| Marlan JD, Chief Officer | ||
| Bharat Warrier, Chief Officer |
TherapeuticsMD Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is TherapeuticsMD a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0665 | ||||
| Profit Margin | (2.08) % | ||||
| Operating Margin | (1.57) % | ||||
| Current Valuation | 12.27 M | ||||
| Shares Outstanding | 11.53 M | ||||
| Shares Owned By Insiders | 1.92 % | ||||
| Shares Owned By Institutions | 30.60 % | ||||
| Number Of Shares Shorted | 155.75 K | ||||
| Price To Earning | (10.22) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether TherapeuticsMD is a strong investment it is important to analyze TherapeuticsMD's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact TherapeuticsMD's future performance. For an informed investment choice regarding TherapeuticsMD Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TherapeuticsMD. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade TherapeuticsMD Stock refer to our How to Trade TherapeuticsMD Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TherapeuticsMD. If investors know TherapeuticsMD will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TherapeuticsMD listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.35) | Revenue Per Share | Quarterly Revenue Growth (0.47) | Return On Assets | Return On Equity |
The market value of TherapeuticsMD is measured differently than its book value, which is the value of TherapeuticsMD that is recorded on the company's balance sheet. Investors also form their own opinion of TherapeuticsMD's value that differs from its market value or its book value, called intrinsic value, which is TherapeuticsMD's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TherapeuticsMD's market value can be influenced by many factors that don't directly affect TherapeuticsMD's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TherapeuticsMD's value and its price as these two are different measures arrived at by different means. Investors typically determine if TherapeuticsMD is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TherapeuticsMD's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.